Compare MAPS & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAPS | MXCT |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | United States | United States |
| Employees | 449 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.7M | 81.6M |
| IPO Year | N/A | 2021 |
| Metric | MAPS | MXCT |
|---|---|---|
| Price | $0.66 | $0.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.61 | ★ $5.50 |
| AVG Volume (30 Days) | 685.1K | ★ 980.9K |
| Earning Date | 03-12-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | $18.61 |
| Revenue Next Year | $6.17 | $22.36 |
| P/E Ratio | $9.75 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.60 | $0.64 |
| 52 Week High | $1.36 | $2.96 |
| Indicator | MAPS | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 38.20 |
| Support Level | $0.65 | $0.64 |
| Resistance Level | $0.88 | $0.87 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 36.79 | 18.48 |
WM Technology Inc operates an online cannabis marketplace for consumers, together with a comprehensive set of e-commerce and compliance software solutions for cannabis businesses, which are sold to both storefront locations and delivery operators (retailers) and brands in the legalized cannabis markets in states and territories of the United States. Its comprehensive business-to-consumer and business-to-business suite of products affords cannabis retailers and brands of all sizes integrated tools to compliantly run their businesses and to reach, convert, and retain consumers.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.